Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 5/20 | 0.41 |
| ▸ | DAO | P14920 | 2/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | USP5 | P45974 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3802743 | 0.83 | DAO (0.42) | HTR4DAOMCL1IDO1KMT2A | |
| SCHEMBL6286022 | 0.81 | HTR4 (0.38) | HTR4DAOMCL1KMT2A | |
| SCHEMBL6286028 | 0.81 | HTR4 (0.38) | HTR4DAOMCL1KMT2A | |
| SCHEMBL6532204 | 0.81 | MEN1 (0.42) | DAOKDM4EKMT2ACASP1 | |
| SCHEMBL3807621 | 0.79 | DAO (0.38) | HTR4DAOMCL1KMT2AGAA | |
| SCHEMBL20037330 | 0.78 | KMT2A (0.46) | DAOMCL1KDM4EKMT2A | |
| SCHEMBL1082814 | 0.78 | DAO (0.37) | HTR4DAOMCL1KMT2AGAA | |
| SCHEMBL1082511 | 0.78 | DAO (0.37) | HTR4DAOKDM4EKMT2AGAA | |
| SCHEMBL1081504 | 0.77 | SIGMAR1 (0.39) | HTR4DAOKDM4EGAASIGMAR1 | |
| SCHEMBL4874928 | 0.77 | MCL1 (0.42) | DAOMCL1KDM4EKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050165062-A1 | Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2005-07-28 | — | — | US | disclosed |
| US-6870056-B1 | Substitituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2005-03-22 | — | — | US | disclosed |
| US-6867217-B1 | Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2005-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165062-A1 | Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade | TFPI, PLAT, TFPI2 | HTR4 898/4885DAO 335/4885MCL1 3125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.